SP-420

Abfero Pharmaceuticals

Dedicated to treating diseases of iron overload

info@AbFero.com

SP-420

Our Lead CAndidate

our mission

Abfero Pharmaceuticals Inc. is a clinical stage pharmaceutical company focused exclusively on iron as a therapeutic target. Our mission is to develop best-in-class oral iron chelators for the treatment of diseases of iron overload. Patients with systemic iron overload due to transfusions or genetic conditions are at risk for severe organ damage and death. In addition, iron accumulation in the retina and brain are associated with a number of retinal and neurologic diseases leading to vision loss, neurodegeneration, and other debilitating conditions. Our lead, brain-penetrant small molecule SP-420 may prove an important addition to existing chelating therapies.

Multiple Indications

There are two types of iron overload disorders: systemic iron overload and local iron overload. Patients’ need for an effective, safe and tolerable treatment for both conditions is rapidly rising with the growing population of aging patients. Our small molecule technology and clinical stage pipeline is moving urgently to meet this expanding need.

Age-Related Macular degeneration

AMD is the leading cause of irreversible blindness in the United States. Approximately 11 million people currently live with some form of AMD. Removing iron from the retina may offer a novel approach to address retinal degeneration.

Learn more

Transfusional Iron Overload

Systemic iron overload is a common complication of transfusions, which can lead to severe organ damage and death. Our highly tolerable small molecule technology, and novel dosing regimen shows tremendous promise in addressing this concern.

Learn more

SP-420

AbFero Phamaceuticals, Inc

Dedicated to treating diseases of iron overload

Copyright © AbFero Pharmaceuticals | Privacy Policy & Terms of Use